Trial Profile
A Randomized Phase III Trial Of Gemcitabine Plus Bevacizumab (NSC 704865 IND 7621) Versus Gemcitabine Plus Placebo In Patients With Advanced Pancreatic Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Mar 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Gemcitabine
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Biomarker; Pharmacogenomic; Therapeutic Use
- 01 Feb 2022 Results from TARGET study and four (CALGB/Alliance) clinical trials identifying predictive biomarkers of hypertension induced by these drugs using a discovery-replication approach published in the Pharmacogenomics Journal
- 06 Oct 2021 Results of a meta-analysis of a for clinical studies assessing genome-wide association with either hypertension or proteinuria across the different studies (NCT00785291, NCT00601900, NCT00088894 and NCT00110214) published in the British Journal of Cancer
- 01 Feb 2012 Health-related quality-of-life substudy results published in the Journal of Pain and Symptom Management.